Association of CSF GAP-43 and APOE ε4 with Cognition in Mild Cognitive Impairment and Alzheimer's Disease

被引:7
|
作者
Zhu, Yueli [1 ]
Guo, Xiaoming [2 ]
Zhu, Feng [1 ]
Zhang, Qin [1 ,3 ]
Yang, Yunmei [1 ,3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Geriatr, Hangzhou 310003, Peoples R China
[2] Tongde Hosp Zhejiang Prov, Dept Neurosurg, Hangzhou 310012, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Key Lab Diag & Treatment Aging & Phys Chem Injury, Hangzhou 310003, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; growth-associated protein 43; Apolipoprotein E epsilon 4; synaptic loss; biomarker; AMYLOID-BETA; SYNAPSE LOSS; PROTEIN; TAU; NEUROGRANIN; GENOTYPE; CA1;
D O I
10.3390/cells12010013
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The growth-associated protein 43 (GAP-43) is a presynaptic phosphoprotein in cerebrospinal fluid (CSF). The epsilon 4 allele of apolipoprotein E (APOE) is an important genetic risk factor for Alzheimer's disease (AD). We aimed to evaluate the association of CSF GAP-43 with cognition and whether this correlation was related to the APOE epsilon 4 status. We recruited participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, and they were divided into cognitively normal (CN) epsilon 4 negative (CN epsilon 4-), CN epsilon 4 positive (CN epsilon 4+), mild cognitive impairment (MCI) epsilon 4 negative (MCI epsilon 4-), MCI epsilon 4 positive (MCI epsilon 4+), AD epsilon 4 negative (AD epsilon 4-), and AD epsilon 4 positive (AD epsilon 4+) groups. Spearman's correlation was utilized to evaluate the relationship between CSF GAP-43 and core AD biomarkers at the baseline. We performed receiver-operating characteristic (ROC) curve analyses to investigate the diagnostic accuracy of CSF GAP-43. The correlations between CSF GAP-43 and the Mini-Mental State Examination (MMSE) scores and brain atrophy at baseline were assessed by using multiple linear regression, while the association between CSF GAP-43 and MMSE scores at the follow-up was tested by performing the generalized estimating equation (GEE). The role of CSF GAP-43 in the conversion from MCI to AD was evaluated using the Cox proportional hazard model. We found that the CSF GAP-43 level was significantly increased in MCI epsilon 4+, AD epsilon 4- and AD epsilon 4+ groups compared with CN epsilon 4- or MCI epsilon 4- group. The negative associations between the CSF GAP-43 and MMSE scores at the baseline and follow-up were found in MCI epsilon 4- and MCI epsilon 4+ groups. In addition, baseline CSF GAP-43 was able to predict the clinical progression from MCI to AD. CSF GAP-43 may be a promising biomarker to screen cognition for AD. The effects of CSF GAP-43 on cognition were suspected to be relevant to APOE epsilon 4 status.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
    Papaliagkas, Vasileios
    Kalinderi, Kallirhoe
    Vareltzis, Patroklos
    Moraitou, Despoina
    Papamitsou, Theodora
    Chatzidimitriou, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [22] Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease
    Ewers, Michael
    Zhong, Zhenyu
    Buerger, Katharina
    Wallin, Anders
    Blennow, Kaj
    Teipel, Stefan J.
    Shen, Yong
    Hampel, Harald
    BRAIN, 2008, 131 : 1252 - 1258
  • [23] Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease
    Kellar, D.
    Lockhart, S. N.
    Aisen, P.
    Raman, R.
    Rissman, R. A.
    Brewer, J.
    Craft, S.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2021, 8 (03): : 240 - 248
  • [24] Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
    D. Kellar
    S. N. Lockhart
    P. Aisen
    R. Raman
    R. A. Rissman
    J. Brewer
    Suzanne Craft
    The Journal of Prevention of Alzheimer's Disease, 2021, 8 : 240 - 248
  • [25] Alzheimer's Disease and mild cognitive impairment
    Kelley, Brendan J.
    Petersen, Ronald C.
    NEUROLOGIC CLINICS, 2007, 25 (03) : 577 - +
  • [26] Association of Apo E 4 and Mild Cognitive Impairment (MCI) in Alzheimer's disease (AD)
    Divakar, Deepak
    Kumar, Anoop
    Bishnoi, Sanjay
    Sasmal, Dinakar
    Sharma, Neelima
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 : S89 - S89
  • [27] Mild cognitive impairment: Is it Alzheimer's disease or not?
    Petersen, RC
    Bennett, D
    JOURNAL OF ALZHEIMERS DISEASE, 2005, 7 (03) : 241 - 245
  • [28] Mild cognitive impairment: Is it Alzheimer's disease?
    Peteren, R.
    CLINICAL NEUROPSYCHOLOGIST, 2007, 21 (04) : 687 - 687
  • [29] EEG microstates - association with cognitive impairment and Alzheimer's Disease CSF biomarkers
    Smailovic, U.
    Koenig, T.
    Andersson, T.
    Laukka, E. Jonsson
    Kalpouzos, G.
    Winblad, B.
    Jelic, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 52 - 52
  • [30] An Abbreviated MoCA to Differentiate Normal Cognition, Mild Cognitive Impairment, and Alzheimer's Disease
    Horton, D.
    Ream, D.
    Pandya, S.
    Clem, M.
    Hynan, L.
    Rossetti, H.
    Lacritz, L.
    Cullum, M.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2014, 29 (06)